- Home
- OM vs IMA Comparison
OM vs IMA Comparison
Compare OM & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.62
N/A
Current Price
$6.49
Company Overview
Basic Information| Metric | OM | IMA |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | United States |
| Employees | 310 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.9M | 65.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | OM | IMA |
|---|---|---|
| Price | $3.62 | $6.49 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | $13.33 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 298.2K | 43.1K |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $119,476,000.00 | N/A |
| Revenue This Year | $9.16 | N/A |
| Revenue Next Year | $11.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.09 | N/A |
| 52 Week Low | $0.53 | $5.70 |
| 52 Week High | $21.98 | $17.50 |
Technical Indicators
Market Signals| Indicator | OM | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 41.48 | 45.20 |
| Support Level | $3.12 | $6.58 |
| Resistance Level | $4.97 | $7.17 |
| Average True Range (ATR) | 0.34 | 0.37 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 25.88 | 12.09 |
Price Performance
Historical Comparison OM
IMA
About OM Outset Medical Inc.
Outset Medical Inc is a medical technology company pioneering a technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.